Democratic Strategist Warns DNC Election Autopsy Suggests Midterm Wins May Be by Default April Jobs Report Preview Low Payroll Growth Expected as Labor Market Shows Signs of Cooling AIDriven Drug Discovery May Accelerate Treatments for Brain Conditions Like MND UK Exports to US Plunge 25 Following Trumps Liberation Day Tariffs Trade Balance Turns to Deficit Trump Postpones AI Executive Order Signing Citing Concerns Over Potential Regulatory Barriers 110th Indianapolis 500 Viewing Guide and Potential Economic Impact PRM Q1 2026 Earnings EPS Surges 197 Above Estimates but Stock Declines MFAO Q1 2026 Earnings Narrow Earnings Miss Reflects Stable mREIT Performance MOLN Q4 2025 Earnings Positive EPS Surprise Amid No Revenue PRME Q1 2026 Earnings WiderthanExpected Loss but Shares Surge 11 Telomir Pharmaceuticals Inc TELO Q4 2025 Earnings Significant EPS Miss Amid PreClinical Stage Operations MBIA Q1 2026 Earnings Deep Losses Underscore Continued Credit Portfolio Challenges Brandywine Realty Trust BDN Holds Near 300 as Bulls Test Resistance Zone Uxin UXIN Surges Over 6 as Stock Tests Key Resistance Near 250 Southern Company Preferred Stock SOJE Edges Higher Testing Key Resistance uniQure QURE Sheds Fractional Ground as Gene Therapy Stock Consolidates Near Support Kaiser Aluminum KALU Holds Steady Near 187 as Resistance Looms Dropbox CEO Drew Houston Steps Down Transitions to Executive Chairman Role MRVI Q1 2026 Earnings EPS Surprise of 12079 Drives Focus on Cost Control Amid Revenue Uncertainties CollPlant Biotechnologies CLGN Slips Slightly as Stock Tests Key Support near 040 SFIX Q1 2026 Earnings NarrowerThanExpected Loss Signals Cost Control Progress KB Financial Group Q4 2025 Earnings Earnings Beat Estimates Amid Steady Performance Maximus MMS Q1 2026 Earnings EPS Beats Estimates Stock Slightly Down FWRG Q1 2026 Earnings EPS Misses Estimates Stock Declines ATAI Q1 2026 Earnings NarrowerThanExpected Loss Fails to Lift Shares SBEV Q2 2025 Earnings Widerthanexpected loss sends shares lower LIXT Q4 2024 Earnings ClinicalStage Biotech Reports perShare Loss as Development Continues